Osimertinib and NSCLC Treatment
5 Questions
0 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the main focus of the study mentioned in the text?

  • Investigation of chemotherapy resistance mutations in NSCLC
  • Comparison of Osimertinib with and without Chemotherapy in EGFR-mutated NSCLC (correct)
  • Assessment of chemotherapy as a first-line treatment for NSCLC
  • Evaluation of third-generation EGFR-TKI inhibitors in NSCLC treatment

    • What type of trial design was used in the study?

  • Phase 1, single-center, double-blind trial
  • Phase 3, international, open-label trial (correct)
  • Observational cohort study
  • Phase 2, multicenter, randomized controlled trial

    • What is the primary target of Osimertinib?

  • ALK gene mutations
  • KRAS gene mutations
  • EGFR-TKI–sensitizing and EGFR T790M resistance mutations (correct)
  • ROS1 gene mutations

    • What is the potential benefit of adding chemotherapy to EGFR-TKI therapy, as suggested by evidence?

    <p>Extension of the benefits of EGFR-TKI therapy</p> Signup and view all the answers

    Which genetic mutations were considered in the selection of patients for the study?

    <p>EGFR-mutated (exon 19 deletion or L858R mutation)</p> Signup and view all the answers

    Use Quizgecko on...
    Browser
    Open
    Browser
    Browser